Specifically, that could include a ban on spread pricing – when a PBM reimburses pharmacies one price for a medicine, but ...

Its rare disease pipeline includes sickle cell disease therapy etavopivat, currently in the phase 2/3 HIBISCUS trial due to ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...

The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the first drug for ...

Recruiting for clinical trials is hard… and expensive. And a large component of that time involves people sifting through ...

In a time when pharmaceutical companies no longer have the economic luxury of decades-long development cycles, indication ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...

The analysis found that across all the 339 appraisals carried out for the new medicines, the median gain in quality-adjusted ...

A new study has confirmed that the rate of colorectal cancer is rising in younger adults around the world, with England among ...

Investors seemed to panic after the announcement, with a sell-off driving Keros' share price down 73%, reversing strong gains ...

Private equity group Carlyle has joined forces with other investors on a €900 million-plus recapitalisation of UK drugmaker ...

Essentially, what Concr demonstrates is that training their algorithms on smaller, yet more diverse, data can lead to increased accuracy, due to the broader biological variability within that training ...